65,437 trials
Vitamin D Status · Healthy
Primary: Serum Levels of 25hydroxy Vitamin D(25(OH)D)Compared to the Due Control Group — 21.6; 21.2; 33.3; 31.5 nmol/L
Hypertension · Coronary Artery Disease
Primary: Peripheral Diastolic Blood Pressure (DBP) — 81.1; 78.2; 78.0; 79.3 mmHg
Congestive Heart Failure · Cardiomyopathy · Dyspnea
Primary: Number of Subjects With at Least 30 Days of Daily Impedance Measurements — 47; 106 participants
Colonoscopy
Primary: Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale — 77.6; 80.1 percent of participants — p=0.005
Liver Cirrhosis
Primary: Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at 0.5, 1, and 1.5 Hours Post Dose — 16.58; 18.33; 15.80; 0.33 mmHg
Post-stroke Upper Limb Spasticity
Primary: Number of Participants With Reduction of at Least 1 Point at Week 4 Compared to Baseline in Ashworth Score in Wrist Flexors — 50; 28 Participants — p=<0.001
Osteoarthritis
Primary: The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site. — 12.3; 17.2 days…
Autistic Disorder · Autism
Primary: Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale — -3.5; -7.4; -12.4 units on a scale — p=<0.001
Healthy Volunteers
Primary: The Comparison of BTDS to Placebo Transdermal System (TDS): the Average Difference From Baseline Using QT Corrected From Within-subject Data (QTci) on Day 13 — 4.20…
Hand Dermatosis
Primary: Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score — 96.7 Percentage of…
Pulmonary Disease, Chronic Obstructive
Primary: Actuations Registered by the Actuation Indicator — 167 Count
Neuropathic Pain
Primary: Mean Change From Baseline in Dynamic Allodynia Intensity at Visits 3 and 6 and Visits 4 and 7 — -1.09; -1.16; -1.31; -0.67 scores on a scale — p=0.7319
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 324; 241 days — p=0.00583
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…
Meningococcal Infections · Meningococcal Meningitis
Primary: Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years — 29; 33; 31; 77 Titers